Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure

European Journal of Heart Failure

Volumn 4, Issue 4, 2002, Pages 445-453

  Refsgaard, Jens ^a,b   Thomsen, Claus ^a   Andreasen, Frederik ^b   Gøtzsche, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Beta blockade; Congestive heart failure; Insulin resistance; Minimal model

Indexed keywords

ACETYLSALICYLIC ACID; ACTRAPID HUMAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIURETIC AGENT; INSULIN; NITRATE; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WEIGHT; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; VASODILATOR AGENTS;

EID: 0036673266     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00035-1     Document Type: Article

References (47)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS, Oliver MF. Insulin resistance in chronic heart failure. Eur. Heart J. 1994;15:1528-32.
3. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 1997;30:527-32.
4. Swedberg K, Eneroth P, Kjekhus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure. Circulation 1990;82:1730-6.
5. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognoses in patients with chronic congestive heart failure. N. Eng. J. Med. 1984;11:19-823.
6. Scherrer U, Sartori C. Insulin as a vascular and sympatho excitatory hormone. Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-13.
7. US Carvedilol Heart Failure Study Group, Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Eng. J. Med. 1996;334:1349-55.
8. The Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
9. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 1992;19(Suppl 1):S68-S80.
10. National Cholesterol Education Program (Expert Panel (1993)). Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
11. Bergman RN. Toward physiological understanding of glucose tolerance. Minimal model approach. Diabetes 1989;38:1512-27.
12. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endoc. Rev. 1985;6:45-86.
13. Peterson JI, Young DS. Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal. Biochem. 1968;23:301-16.
14. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin. Chem. 1993;394:578-82.
15. Eriksson BM, Persson BA. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J. Chromatogr. 1982;228:143-54.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1983;29:1075-80.
17. Schiller NB, Shah PM, Crawford PM. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J. Am. Soc. Echocardiogr. 1989;2:358-67.
18. Åkstrand PO. Quantification of exercise capability and evaluation of physical capacity in man. Prog. Cardiovasc. Dis. 1976;14:51-67.
19. Thomsen C, Rasmussen O, Christiansen C, et al. Comparison of the effects of a monounsaturated fat diet and a high carbohydrate diet on cardiovascular risk factors in first degree relatives to Type-2 diabetic subjects. Eur. J. Clin. Nutr. 1999;53:818-23.
20. Deprès JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Eng. J. Med. 1996;334:952-7.
21. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J. Hypertens. 1995;13:1457-62.
22. Båvenholm P, Proudler A, Tornvall P, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995;92:1422-9.
23. Paolisso G, De Riu S, Marrazzo G, Verza M, Vamcchio M, D'Onofrio F. Insulin resistance and hyperinsulinaemia in patients with chronic congestive heart failure. Metabolism 1991;40:972-7.
24. Marangou AG, Alford FP, Ward G. Hormonal effects of norepinephrine on acute glucose disposal in humans. A minimal model analysis. Metabolism 1988;77:885-91.
25. Sacca L, Marrone G, Cicala M. Influence of epinephrine, norepinephrine and isoprotenerol on glucose homeostasis in man. J. Clin. Endocrinol. Metab. 1980;50:680-4.
26. Lembo G, Napoli N, Capaldo B. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J. Clin. Invest. 1992;90:24-9.
27. Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration. J. Clin. Invest. 1989;84:1403-9.
28. O'Hara JA, Minaker KL, Meneilly GS, Rowe JW, Palotta JA, Young JB. Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. Metabolism 1989;38:322-9.
29. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995;25:560-3.
30. Grover A, Padington C, Wilson MF, Hee Sung B, Izzo JL, Dandona JP. Insulin attenuates norepinephrine-induced vasoconstriction. An ultrasonographic study. Hypertension 1995;25:779-84.
31. Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence form intraneural recordings. Ann. Intern. Med. 1991;114:373-80.
32. Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-9.
33. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994;23:450-5.
34. Pollare T, Lithell HO, Berne C. A comparison of the effects of hydrochlorthiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Eng. J. Med. 1989;321:868-73.
35. Pollare T, Lithell HO, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-20.
36. Pollare T, Lithell HO, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152-7.
37. Maiminiemi K, Lahtela JT, Huupponen R. Effect of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. Int. J. Clin. Pharmacol. Ther. 1995;32:156-63.
38. 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455-61.
39. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J. Hypertens. 1996;14:489-94.
40. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized controlled trial. Ann. Intern. Med. 1997;126:955-9.
41. Lithell H, Andersson PE. Metabolic effects of carvedilol in hypertensive patients. Eur. J. Clin. Pharmacol. 1997;52:13-7.
42. Wallhaus TR, Taylor M, De Grado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441-6.
43. Melchior T, Rask-Madsen C, Torp-Pedersen C, Hildebrandt P, Kober L, Jensen G. The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15-year follow study. Eur. J. Heart Fail 2001;3:83-90.
44. Gottleib SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Eng. J. Med. 1998;339:489-97.
45. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000;84:615-9.
46. Younis N, Burnham P, Patwala A, Weston PJ, Vora JP. Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabet. Med. 2001;18:159-61.
47. Swan JW, Walton C, Godsland IF. Assessment of insulin sensitivity in man: a comparison of Minimal model and euglycaemic clamp derived measures in health and heart failure. Clin. Sci. 1994;86:317-22.